Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Results of a Phase Ib study of ibrutinib + obinutuzumab in R/R CLL

Christine Ryan, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses updated results of a Phase Ib study investigating the use of ibrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Ryan first gives some background information on this study, and also highlights the safety and efficacy of this treatment combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.